Pay in 4 interest-free payments of $6.69 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
If side effects are particularly troublesome, your healthcare team might consider a slower dose titration schedule or temporarily reducing your dose
Compliance News | November 11, 2025 The administration, together with pharmaceutical manufacturers Eli Lilly and Novo Nordisk, announced an agreement to lower prices and expand access to glucagon-like peptide-1 receptor agonists (GLP-1s) for weight loss for those in the Medicare Part D and Medicaid programs as well as direct-to-consumer (DTC) purchasing
How do I know if I am a suitable candidate
Patients typically experience appetite suppression after a few days of starting the medication
When switching the GLP-1 component to tirzepatide, your provider may adjust or temporarily discontinue the phentermine during titration to isolate the effects of the new medication and manage side effects individually
Fasting plasma glucose typically improves earlier, with noticeable reductions within the first month
